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Accepted 24 December 2014; Published online 11 March 2015AbstractObjectives: To describe the use and reporting of interrupted time series methods in drug utilization research.
Study Design and Setting: We completed a systematic search of MEDLINE, Web of Science, and reference lists to identify English
language articles through to December 2013 that used interrupted time series methods in drug utilization research. We tabulated the number
of studies by publication year and summarized methodological detail.
Results: We identified 220 eligible empirical applications since 1984. Only 17 (8%) were published before 2000, and 90 (41%) were
published since 2010. Segmented regression was the most commonly applied interrupted time series method (67%). Most studies assessed
drug policy changes (51%, n 5 112); 22% (n 5 48) examined the impact of new evidence, 18% (n 5 39) examined safety advisories, and
16% (n 5 35) examined quality improvement interventions. Autocorrelation was considered in 66% of studies, 31% reported adjusting for
seasonality, and 15% accounted for nonstationarity.
Conclusion: Use of interrupted time series methods in drug utilization research has increased, particularly in recent years. Despite
methodological recommendations, there is large variation in reporting of analytic methods. Developing methodological and reporting stan-
dards for interrupted time series analysis is important to improve its application in drug utilization research, and we provide recommen-
dations for consideration.  2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: ARIMA; Drug utilization; Pharmacoepidemiology; Review; Segmented regression; Time seriesConflict of interest: None.
Funding: This research was supported by an Ontario Ministry of
Research and Innovation Early Researcher Award held by S.M.C. S.M.C
was supported by a Canadian Institutes of Health Research (CIHR) New
Investigator Award (MSH-95364). R.J. received support from the CIHR
Training Program in Bridging Scientific Domains for Drug Safety and
Effectiveness.
This research was presented at the International Conference on Pharma-
coepidemiology and Therapeutic Risk Management (ICPE) in Montreal,
QC, Canada, August 2013; the Canadian Association for Population Ther-
apeutics (CAPT) Annual Conference in Toronto, ON, Canada, November
2013; and the Canadian Association for Health Services and Policy
Research (CAHSPR) Annual Conference in Toronto, ON, Canada, May
2014. Participation at ICPE was supported by an ICPE Travel Scholarship,
participation at CAPT was supported by a CAPT Student Bursary and the
Leslie Dan Faculty of Pharmacy Student Experience Fund, and participation
at CAHSPR was supported by a University of Toronto School of Graduate
Studies Conference Grant.
* Corresponding author. Tel.: 416-978-2993; fax: 416-978-8511.
E-mail address: s.cadarette@utoronto.ca (S.M. Cadarette).
http://dx.doi.org/10.1016/j.jclinepi.2014.12.018
0895-4356/ 2015 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).1. Introduction
Interrupted time series analysis is the strongest and most
commonly used quasi-experimental design to assess the
impact of an intervention when a randomized controlled
trial is not feasible [1e6]. This method has been applied
in a variety of disciplines and was first introduced to the
field of health services research in 1981 to evaluate the
impact of regionalized perinatal care [7]. Interrupted time
series methods use aggregate data collected over equally
spaced intervals before and after an intervention, with the
key assumption that data trends before the intervention
can be extrapolated to predict trends had the intervention
not occurred [3]. Routinely maintained pharmacy and med-
ical databases provide rich data sources to apply interrupted
time series methods [3].
Several methodological issues need to be considered
when completing an interrupted time series analysis. First,ess article under the CC BY-NC-ND license (http://creativecommons.org/
951ical Epidemiology 68 (2015) 950e956What is new?
 There has been an increase in the application of in-
terrupted time series analysis in drug utilization
research, particularly in recent years.
 We identified large variation in methodological
considerations reported in empirical applications.
 Developing methodological and reporting stan-
dards for interrupted time series analysis is impor-
tant to improve its application in drug utilization
research, and we provide recommendations for
consideration.
R. Jandoc et al. / Journal of Clingiven the serial nature of the design, autocorrelation, non-
stationarity, and seasonality need to be considered [3,8].
Autocorrelation refers to the serial dependence of outcome
measure error terms. For example, prescription patterns
closer to each other may be more similar than those further
apart [3,5,6]. The presence of autocorrelation can be
assessed using the LjungeBox chi-square statistic [9] or
DurbineWatson statistic [3,5,6,10] and corrected for if
necessary. Nonstationary data exhibit an underlying trend
that is unrelated to the intervention. For example, the use
of a drug commonly increases once it enters the market
[8]. Nonstationary can be tested using the augmented Dick-
eyeFuller test [11]. Seasonality represents regular seasonal
fluctuations in the outcome, for example, use of medica-
tions to treat influenza. When present, terms for seasonality
(e.g., months) should be included in the model [3,6].
Failing to account for autocorrelation, nonstationarity, and
seasonality may lead to biased results.
The number of data points available for analysis and the
number of observations within each data point are impor-
tant when using interrupted time series analysis. Although
there is no gold standard, it is generally agreed that more
data points and observations are better. Depending on the
minimum effect size and the amount of variation, a mini-
mum of nine data points preintervention, postintervention,
and when applicable, between interventions [4,12], and at
least 100 observations per data point is encouraged [3]. A
larger number of observations in each data point provides
more stable estimates and thus reduces the variability and
outliers within a time series analysis. Data point outliers
that are explainable, such as a sudden peak in drug
dispensing in anticipation of a drug restriction policy, can
be controlled for using an indicator term [3]. Outliers that
result from random variation can be treated as regular data
points [3]. A larger number of data points also permit more
stable estimates for forecasting preintervention trends had
the intervention not occurred. In general, however, caution
should be used when forecasting beyond the data points
observed in interrupted time series analyses. Anothercaveat when conducting interrupted time series analysis re-
lates to possible outcome measure ceiling or floor effects.
For example, when studying the impact of an intervention
in improving the proportion of patients treated with a drug,
the outcome has a natural ceiling of 100%, and thus, de-
pending on the initial level of measurement, minimal
change in the outcome may be observed [13]. Authors must
consider ceiling and floor effects when designing their
study and interpreting results.
A clear intervention time point helps to identify preinter-
vention and postintervention data points, yet if intervention
effects are gradual or delayed, then a lag period may be
considered [3]. Lagged intervention effects can be ac-
counted for by excluding the lag period from the analysis,
modeling the lag period as a separate segment in the time
series [3], or using a ramp function in autoregressive inte-
grated moving average (ARIMA) models [14]. Here, graph-
ical figures displaying the results of interrupted time series
analysis are particularly useful. Even without statistical
output, figures allow readers to visually examine baseline
trends, the time point at which the intervention occurred,
and the impact of the intervention [3,5]. All interrupted
time series studies should therefore include graphical
display to facilitate interpretation of study results.
The main threat to validity in interrupted time series
analysis relates to time-varying confounding, such as
changes in outcome coding, cointerventions, or changes
in the population under study [3e5,15]. These threats need
to be considered at the individual study level and require
intimate knowledge of the data and health care utilization
trends. The use of a comparison outcome in the same pop-
ulation, or a comparison group using the same outcome in a
group not exposed to the intervention, helps to alleviate
concerns related to time-varying confounding [3,5]. Indeed,
an advantage of interrupted time series analysis is the ease
in stratifying results by different groups [5].
Interrupted time series analysis has been applied in a va-
riety of disciplines; however, its use to study the impact of
health care interventions on drug utilization has not been
well described. The purpose of our study was to describe
the use and reporting of interrupted time series methods
in drug utilization research.2. Methods
We completed a systematicMEDLINE keyword andWeb
of Science citation search to identify all English language
articles that used interrupted time series methods to study
drug utilization in humans. Empirical applications that
examined the impact of interventions at the population level,
including drug policy changes, new evidence in the form of
guideline changes or major publications, quality improve-
ment interventions, and government or media safety advi-
sories; on prescription drug utilization were eligible. We
defined drug utilization as the number or proportion of
Fig. 1. Flow diagram of systematic search results. MEDLINE was used
for the keyword search using search terms (Appendix A at www.
jclinepi.com), and Web of Science was used for the citation search
[3,5,7,16].
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meeting an adherence target. Systematic reviews, methodo-
logical contributions, letters to the editor, and conference
abstracts were excluded because the focus was on use and
reporting of empirical applications. We also excluded single
institution studies so we could focus on population-based
interventions that may be more generalizable.
We first searched MEDLINE from inception (1946) to
December 2013 with keyword terms related to time series
analysis and drug utilization (Appendix A at www.jclinepi.
com). We then used Web of Science to perform a citation
search of methodological articles identified in the keyword
search [3,5,16] and a commonly cited article [7]. Finally,
we manually searched reference lists from all methodolog-
ical contributions [B.1e10, Appendix B at www.jclinepi.
com], review articles [B.11e14], and eligible empirical ap-
plications [B.15e203] identified in the keyword and citation
searches to identify additional empirical applications. Two
authors (R.J. and A.M.B.) independently completed each
search and reviewed articles for eligibility. Discrepancies
were resolved through discussion with a third author
(S.M.C.). A proportional Venn diagram was created to illus-
trate the number of empirical applications identified by each
search strategy. The number of empirical applications was
then plotted by publication year.
We abstracted the following characteristics for each
application: intervention(s) of interest, primary data source,
and methodological detail (time intervals, outcome mea-
sure, interrupted time series methods used, and methodo-
logical considerations reported). As previously described,
there are several methodological considerations in interrup-
ted time series analysis, and we have taken care to abstract
whether authors reported these; however, we were unable to
evaluate aspects that would require access to each study’s
raw data. Thus, methodological considerations abstracted
included reporting of autocorrelation, nonstationarity, and
seasonality; use of a comparison group; clearly defined
time points; number of preintervention and postintervention
points; outliers; forecasting; and absolute and/or relative
changes with confidence intervals or standard errors. Addi-
tional considerations abstracted included the use of lag
periods, sensitivity analysis, and graphical figures to
display results. One author (R.J.) abstracted all data, and
a second author (A.M.B.) verified all abstracted data. All
methodological considerations were summarized using
descriptive statistics.Fig. 2. Proportional Venn diagram of search result yield of empirical
applications by search strategy, n 5 220. The size of each circle is
proportional to the relative number of articles identified. MEDLINE
keyword search terms are listed in Appendix A at www.jclinepi.com,
and four articles were used in the Web of Science citation search
[3,5,7,16]. The reference search included all eligible empirical appli-
cations (n 5 189), methods (n 5 10), and reviews (n 5 4) identified
by the keyword and citation searches. One article not indexed in MED-
LINE or Web of Science databases was identified by a reviewer during
the peer-review process [B.212].3. Results
Of 1917 unique articles identified, 10 were methodolog-
ical contributions [B.1e10], 4 were review articles
[B.11e14], and 220 were eligible empirical applications
[B.15e234] (Fig. 1, Appendix B at www.jclinepi.com).
Each search strategy proved important, with 52 empir-
ical applications (24%) identified solely by the keywordsearch, 33 (15%) identified solely by the citation search,
30 (14%) identified solely by the reference list search,
and only 35 (16%) identified by all three search strategies
(Fig. 2). Most segmented regression articles (92 of 134,
69%) were identified by the citation search, whereas most
ARIMA articles (26 of 31, 84%) were identified by the
keyword search. One eligible article that did not appear
Table 1. Characteristics of interrupted time series applications in drug
utilization, n 5 220a
Characteristic n %
Intervention
Drug policy changes 112 50.9
Copayments or cost sharing 33 15.0
New drug or drug withdrawal 15 6.8
Prior authorization 21 9.5
Reimbursement changes 43 19.5
New evidence 48 21.8
Guideline changes 15 6.8
Major publications 33 15.0
Quality improvement interventions 35 15.9
Educational 18 8.2
Other quality improvement 17 7.7
Safety advisories 39 17.7
Data source
Administrative data 203 92.3
Medical charts 10 4.5
Survey data 7 3.2
Time point intervals
Monthly 166 75.5
Quarterly 31 14.1
Other (e.g., annually, biannually, biweekly,
weekly)
23 10.5
Primary outcome measure
Patient 64 29.1
Number 15 6.8
Proportion 49 22.3
Prescriptions 157 71.4
Number 49 22.3
Proportion 77 35.0
Standardized dose (e.g., daily defined dose) 31 14.1
Interrupted time series method reportedb 200 90.9
ARIMA models 31 15.5
Reported intervention function (e.g., point,
ramp, step)c
18 58.1
Linear regression 22 11.0
Segmented regression 134 67.0
Linear modelsd 67 50.0
Other modelsd (e.g., GEE, logistic, nonlinear) 9 6.7
Not specifiedd 58 43.3
Other regression (e.g., GEE, logistic, nonlinear,
Poisson)
14 7.0
Statistical considerations reported
Autocorrelation 146 66.4
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the peer-review process [B.212].
The first empirical application was published in 1984, yet
relatively few (n 5 17, 8%) were published before the year
2000 (Fig. 3). Since 2000, use has increased with an average
of 15 (standard deviation 5 8.2) applications published per
year. Forty-one percent (n 5 90) were published in the last
4 years, with a high of 31 articles published in 2013.
Table 1 summarizes the characteristics of the 220 empir-
ical applications identified, of which 92% used administra-
tive pharmacy databases. Drug policy changes were the
most common interventions evaluated (51%), followed by
new evidence (22%), safety advisories (18%), and quality
improvement interventions (16%). Seventy-one percent
examined prescriptions dispensed (22% number, 35%, pro-
portion, and 14% standard dose) as the primary outcome
measure, and 29% used the number or proportion of patients
dispensed the drug of interest or meeting an adherence target.
Most applications examined drug utilization over monthly
(76%) or quarterly (14%) intervals. Of the 200 articles
(91%) reporting detailed methods, segmented regression
(67%), ARIMA models (16%), and linear regression (11%)
were the most commonly applied analyses. Other analytical
methods included generalized estimating equations, logistic,
nonlinear, and Poisson models. Fifty percent (n 5 67) of
articles using segmented regression applied a linear model.
Of all empirical studies, 146 (66%) reported testing for
autocorrelation (77% of ARIMA articles and 73% of
segmented regression articles), 68 (31%) reported adjusting
for seasonality (52% of ARIMA and 29% of segmented
regression), and 32 (15%) reported testing for nonstationar-
ity (65% of ARIMA and 9% of segmented regression).
One-third (35%) of all empirical studies reported the use
of a comparison group, 70% reported absolute and/or rela-
tive impacts with confidence intervals or standard errors,
and 28% reported including lag periods in their models.
Most articles (85%) clearly reported the intervention time
point(s) of interest, and 84% of studies included a graph,Fig. 3. Number of interrupted time series empirical applications in
drug utilization research, by publication year, n 5 220.
Comparison group 77 35.0
Confidence intervals or standard errors
reported with estimates
153 69.5
Forecasting using preintervention trends 64 29.1
Graphical figures to display results 184 83.6
Lag periods 61 27.7
Nonstationarity 32 14.5
Number of preintervention and postintervention
data points
86 39.1
Outliers 17 7.7
Seasonality 68 30.9
Sensitivity analysis 45 20.5
Time point clearly defined 186 84.5
Abbreviations: ARIMA, autoregressive integrated moving average;
GEE, generalized estimating equation.
a Some characteristics are not mutually exclusive, thus propor-
tions add to greater than 100%.
b For articles reporting detailed time series methods only,
n 5 200.
c For articles reporting ARIMA only, n 5 31.
d For articles conducting segmented regression only, n 5 134.
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postintervention data points included in their analysis
(range 3e72 data points). One-fifth (21%) of applications
conducted a sensitivity analysis.4. Discussion
We examined the application and reporting of interrup-
ted time series analysis methods in drug utilization
research. Use of interrupted time series analysis has
increased since the year 2000, a finding noted in other
recent reviews of innovative methods in pharmacoepidemi-
ology [17,18]. The most common interrupted time series
methods were segmented regression (67%), ARIMA
models (16%), and linear regression (11%). When
executing time series models, several methodological as-
pects are important and may impact the validity of the
model. We identified that most eligible articles using ARI-
MA models addressed autocorrelation (77%), nonstationar-
ity (65%), and seasonality (52%). Because ARIMA models
inherently account for autocorrelation, nonstationarity, and
seasonality [19], it is possible that authors may have chosen
not to report these considerations. In contrast, segmented
regression models do not intrinsically account for autocor-
relation, nonstationarity, and seasonality, and thus, it is
imperative to consider each [3]. However, only 73% of
segmented regression studies reported testing for autocorre-
lation, 29% reported adjustment for seasonality, and only
9% reported consideration of nonstationarity.
Over 80% of interrupted time series analyses cited a
clearly defined intervention time point and used figures to
graphically display results; however, other methodological
issues were poorly reported. Explicit reporting of all meth-
odological considerations may improve awareness of their
importance and the interpretation of interrupted time series
studies. Therefore, based on prior suggestions [3e6,12,20],
we recommend the following be reported in all interrupted
time series applications: (1) autocorrelation, nonstationar-
ity, and seasonality considerations; (2) intervention time
point(s) and lag periods; (3) the number of data points pre-
intervention, postintervention, and between intervention(s);
(4) specific statistical regression methods and the appropri-
ateness of a linear model when applied; and (5) absolute
and/or relative changes from baseline (intervention impact)
with significance. We also recommend that all interrupted
time series studies: (1) use a graphical display with clearly
defined time point(s) to present results; (2) comment on: the
minimum number of observations per data point, data vari-
ability, ceiling or floor effects; and (3) consider the use of a
comparison group. Authors are also encouraged to discuss
possible data or cointervention confounding issues and pro-
vide a rationale if no comparison group was considered.
These recommendations are summarized in Table 2 and
build from the Strengthening the Reporting of Observa-
tional Studies in Epidemiology statement [21].Our systematic review is subject to some limitations
related to our literature search strategy and inclusion criteria.
First, we recognize that the lack ofMedical Subject Headings
(MeSH terms) and standardized terminology to describe the
interrupted time series design may have resulted in some
missed applications. Although segmented regression was first
introduced to health care research in 1981 [7] and a seminal
method article was published in 2002 [3], we found that many
articles did not use the term ‘‘segmented regression’’ to
describe their analysis. Therefore, particular attention to each
study’s statistical analysis was required during data abstrac-
tion to determine the type of interrupted time series method
used. Second, our search was limited in ability to identify ap-
plications that are not indexed in either of the databases used
(MEDLINE andWeb of Science). Indeed, during the peer re-
view of our article, a blind reviewer identified one eligible
article [B.212] that is not indexed in the databases used and
therefore was not identified in our original search.
Third, by restricting inclusion to studies that examined
prescription drug utilization defined by the number or pro-
portion of prescription drugs dispensed or patients
dispensed a drug, we will have missed interrupted time se-
ries analyses with different drug outcomes, such as illicit
drug use, drug sales, or drug market share [22,23]. Fourth,
we acknowledge that studies examining single institution
interventions (n 5 59, Appendix C at www.jclinepi.com)
were excluded so we could focus on population-based inter-
ventions that may be more generalizable. Despite poten-
tially missing some applications, we feel that our results
that identify an increase in the number of applications in
recent years, and conclusions of the general trends of
methods and underreporting of statistical considerations,
would still hold. Indeed, 66% of the 59 single institution
studies used segmented regression analysis, similar to our
finding that 67% of studies included in our review used
segmented regression analysis.
Finally, we acknowledge that our review is limited by
what authors have reported or presented in their studies,
which may not reflect the true methodological rigor of each
study. Therefore, the large variation in reporting that we
identified may not indicate inappropriate use of interrupted
time series methods but rather a need for reporting stan-
dards to facilitate quality reporting, application, and inter-
pretation of interrupted time series results.
Amajor strength of our systematic review is the use ofmul-
tiple search strategies to identify articles. Our keyword and
citation search yielded 190 eligible articles (86% overall),
with only 31% identified in both.We attribute this small over-
lap to a lack ofMeSH terms for time series analysis. The addi-
tional reference list search of eligible articles identified
another 30 (14% overall) eligible applications not captured
in our prior searches. This observation corroborates the impor-
tance of using multiple search strategies as identified in prior
reviews of new statistical methods [17,18]. We encourage
future systematic reviews to use a similar proportional Venn
diagram to clarify search strategy yield.
Table 2. Methodological and reporting recommendations for interrupted time series studiesa
Item Item no Recommendation
Title and abstract 1 Indicate the study design (interrupted time series) in the title or abstract
Introduction
Background/rationale 2 Provide background regarding the intervention and setting under investigation to support the study
rationale and methods
Objectives 3 (a) State specific objectives and any prespecified hypotheses
(b) Distinguish between primary and secondary objectives
Methods
Intervention 4 Define the intervention time point(s) used in the analysis
Participants 5 (a) List eligibility criteria and methods of selection
(b) Define subgroups
(c) Consider including a comparison group not exposed to the intervention as a secondary group of
participants
Data sources and
measurement
6 (a) List data source(s)
(b) Comment on data completeness, validity, and changes in data coverage over time
Variables 7 (a) Define all variables
 Outcome variable(s)
 Descriptive and stratifying variable(s)
(b) Comment on change in variable coding over time
(c) Consider including details of variable coding in supplemental material, for example, appendix or
research Web site
Statistical methods 8 (a) Report all statistical methods
 Study time intervals, for example, monthly, quarterly
 Regression model, for example, ARIMA, linear, segmented
B For ARIMA models, indicate the intervention function, for example, point, ramp, or step
B Indicate the appropriateness of linear model(s) when applied
 Number of preintervention, postintervention, and between intervention data points
(b) Define the study period and number of preintervention data points used in forecasting
(c) Indicate how autocorrelation, nonstationarity, and seasonality were tested and handled
(d) Consider a lag period if intervention effects are gradual or delayed
(e) Define and distinguish between primary and secondary or sensitivity analyses
(f) Consider use of comparison outcome(s) and/or population(s) not exposed to the intervention(s) as
secondary analyses
(g) Report statistical software used for analysis
Results
Participants 9 (a) Report the number of individuals and/or observations in each group analyzed
(b) Consider use of a flow diagram
(c) Describe characteristics and indicate missing data
Outcome data 10 (a) Report the number of outcomes examined over the study period
(b) Report the average, minimum, and maximum number of outcomes across time intervals
(c) Report on data variability
(d) Comment on outliers and ceiling or floor effects where relevant
Main results 11 (a) Present results using a graphical display with intervention time point(s) clearly defined
(b) Consider including forecasted results graphically
(c) Report absolute and/or relative change(s) and their significance, for example, clinical or policy
and statistical
Other analyses 12 Report additional results (secondary and sensitivity analyses) in the article, appendix, or research Web site
Discussion
Key results 13 Summarize key results with reference to study objectives
Context 14 (a) Provide context related to possible confounding
 Discuss relevant cointerventions that occurred during the study period
 Comment on the stability of participant characteristics over time
 Comment on the stability of outcome coding over time
(b) Discuss results of comparison analyses or provide a rationale if no comparison group was considered
Limitations 15 (a) Discuss limitations of the study
(b) Comment on data variability and appropriateness of the number of data points
(c) Comment on ceiling or floor effects and outliers where relevant
(d) Discuss direction and magnitude of any potential bias
Interpretation 16 Provide overall interpretation of results considering objectives, limitations, results from similar studies, and
other relevant evidence
Other information
Funding 17 List funding source(s) and role of funders
References 18 Reference methodological articles that support statistical methods used
Abbreviations: ARIMA, autoregressive integrated moving average; GEE, generalized estimating equation.
a Items adapted from the Strengthening the Reporting of Observational Studies in Epidemiology statement [21].
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956 R. Jandoc et al. / Journal of Clinical Epidemiology 68 (2015) 950e956In summary, we identified an increase in the number of
applications of interrupted time series analysis to examine
interventions in drug utilization, particularly in recent
years. When properly executed, interrupted time series
analysis is a valuable method to evaluate the success, fail-
ure, or unintended consequences of health care interven-
tions on drug utilization [24]. However, there is large
variation in the reporting of interrupted time series
methods. Developing methodological and reporting stan-
dards for interrupted time series analysis is important to
improve its application in drug utilization research. We pro-
vide a summary table of methodological and reporting rec-
ommendations for researchers to consider when completing
interrupted time series analyses.
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